| 106677-8 | Date of first screening for shortness of breath during assessment period | SURVEY.CMS |
| 106678-6 | Did the screening indicate the patient had shortness of breath during assessment period (qualitative) | SURVEY.CMS |
| 106679-4 | Treatment for Shortness of Breath during assessment period | PANEL.SURVEY.CMS |
| 10668-2 | Fungus identified in Specimen (environmental culture) | MICRO |
| 106680-2 | Was treatment for shortness of breath initiated during assessment period (qualitative) | SURVEY.CMS |
| 106681-0 | Date treatment for shortness of breath initiated during assessment period | SURVEY.CMS |
| 106682-8 | Symptom Impact during assessment period | PANEL.SURVEY.CMS |
| 106683-6 | Date of symptom impact screening during assessment period | SURVEY.CMS |
| 106684-4 | Was a symptom impact screening completed during assessment period (qualitative) | SURVEY.CMS |
| 106685-1 | Symptom Impact Screening during assessment period | PANEL.SURVEY.CMS |
| 106686-9 | 7-Aminomeclonazepam (Urine, confirmatory method) | DRUG/TOX |
| 106687-7 | Isavuconazole | DRUG/TOX |
| 106688-5 | Symptom Impact - Pain during assessment period (qualitative) | SURVEY.CMS |
| 106689-3 | Symptom Impact - Shortness of breath during assessment period (qualitative) | SURVEY.CMS |
| 10669-0 | Fungus identified in Specimen (sticky tape for environmental fungus) | MICRO |
| 106690-1 | Symptom Impact - Anxiety during assessment period (qualitative) | SURVEY.CMS |
| 106691-9 | Symptom Impact - Vomiting during assessment period (qualitative) | SURVEY.CMS |
| 106692-7 | Symptom Impact - Nausea during assessment period (qualitative) | SURVEY.CMS |
| 106693-5 | Symptom Impact - Diarrhea during assessment period (qualitative) | SURVEY.CMS |
| 106694-3 | Symptom Impact - Constipation during assessment period (qualitative) | SURVEY.CMS |
| 106695-0 | Symptom Impact - Agitation during assessment period (qualitative) | SURVEY.CMS |
| 106696-8 | SFV Symptom Impact - Agitation during assessment period (qualitative) | SURVEY.CMS |
| 106697-6 | SFV Symptom Impact - Constipation during assessment period (qualitative) | SURVEY.CMS |
| 106698-4 | SFV Symptom Impact - Diarrhea during assessment period (qualitative) | SURVEY.CMS |
| 106699-2 | SFV Symptom Impact - Vomiting during assessment period (qualitative) | SURVEY.CMS |
| 1067-8 | Jk sup(a) Ab from Blood product unit (qualitative) | BLDBK |
| 10670-8 | Giardia lamblia (Stool, qualitative, organism specific culture) | MICRO |
| 106700-8 | SFV Symptom Impact - Nausea during assessment period (qualitative) | SURVEY.CMS |
| 106701-6 | SFV Symptom Impact - Anxiety during assessment period (qualitative) | SURVEY.CMS |
| 106702-4 | SFV Symptom Impact - Shortness of breath during assessment period (qualitative) | SURVEY.CMS |
| 106703-2 | SFV Symptom Impact - Pain during assessment period (qualitative) | SURVEY.CMS |
| 106704-0 | Symptom Follow-up Visit during assessment period | PANEL.SURVEY.CMS |
| 106705-7 | Was an in-person SFV completed during assessment period (qualitative) | SURVEY.CMS |
| 106706-5 | Date of in-person SFV during assessment period | SURVEY.CMS |
| 106707-3 | Reason SFV Not Completed during assessment period (qualitative) | SURVEY.CMS |
| 106708-1 | SFV Symptom Impact during assessment period | PANEL.SURVEY.CMS |
| 106709-9 | Skin Conditions. Does the patient have one or more skin conditions during assessment period (qualitative) | SURVEY.CMS |
| 10671-6 | Helminth identified in Specimen | MICRO |
| 106710-7 | Types of Skin Conditions during assessment period | SURVEY.CMS |
| 106711-5 | Skin and Ulcer or Injury Treatments during assessment period | SURVEY.CMS |
| 106712-3 | Date bowel regimen initiated or continued during assessment period | SURVEY.CMS |
| 106713-1 | Was a bowel regimen initiated or continued during assessment period (qualitative) | SURVEY.CMS |
| 106714-9 | Date PRN opioid initiated or continued during assessment period | SURVEY.CMS |
| 106715-6 | Bowel Regimen during assessment period | PANEL.SURVEY.CMS |
| 106716-4 | Was a PRN opioid initiated or continued during assessment period (qualitative) | SURVEY.CMS |
| 106717-2 | PRN Opioid during assessment period | PANEL.SURVEY.CMS |
| 106718-0 | Scheduled Opioid during assessment period | PANEL.SURVEY.CMS |
| 106719-8 | Was a scheduled opioid initiated or continued during assessment period (qualitative) | SURVEY.CMS |
| 10672-4 | Helminth+Arthropod identified in Specimen | MICRO |
| 106720-6 | Date scheduled opioid initiated or continued during assessment period | SURVEY.CMS |